Last reviewed · How we verify

Fibrin Sealant 2 (FS2)

Ethicon, Inc. · Phase 3 active Small molecule

Fibrin Sealant 2 is a topical hemostatic agent that forms a fibrin clot to seal wounds and control bleeding during surgical procedures.

Fibrin Sealant 2 is a topical hemostatic agent that forms a fibrin clot to seal wounds and control bleeding during surgical procedures. Used for Hemostasis and tissue sealing during general surgery, Hemostasis during cardiovascular surgery, Hemostasis during orthopedic surgery.

At a glance

Generic nameFibrin Sealant 2 (FS2)
Also known asCROSSEAL*, EVICEL*, tissue adhesive
SponsorEthicon, Inc.
Drug classFibrin sealant / Hemostatic agent
TargetFibrinogen and thrombin (coagulation cascade)
ModalitySmall molecule
Therapeutic areaSurgery / Hemostasis
PhasePhase 3

Mechanism of action

FS2 combines human fibrinogen and thrombin to create a cross-linked fibrin matrix at the site of application, mimicking the final stages of the coagulation cascade. This provides rapid hemostasis and tissue adhesion, reducing blood loss during surgery and potentially improving wound healing. The fibrin scaffold is gradually absorbed and replaced by natural tissue remodeling.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: